Virtual kidney-care companies show no consistent benefit despite billions in investment, PHTI finds

Virtual chronic kidney disease (CKD) management companies have attracted billions of dollars in investment, but a new evaluation from the Peterson Health Technology Institute (PHTI) found no consistent evidence that these solutions slow kidney-function decline or reduce overall healthcare spending.

PHTI evaluated eight prominent virtual CKD management solutions, reviewing more than 5,400 articles and other sources of evidence to reach its conclusions. The institute said the findings raise urgent questions for health plans, employers, policymakers and investors who have backed the sector's rapid growth.

According to PHTI, the solutions showed no consistent evidence of slowing kidney-function decline or increasing use of guideline-recommended medications proven to protect kidney health. For a one-million-member Medicare Advantage plan, the companies evaluated manage more than $5 billion in annual healthcare spending, but reduce that spending by only 0.1%, PHTI reported.

The one benefit PHTI's evaluation did identify was narrow in scope. The virtual solutions helped some patients begin dialysis in a planned setting rather than through an emergency "crash" start, but that benefit reached only about 1 in every 1,000 patients with CKD, according to the institute.

The findings arrive against a backdrop of substantial disease burden. CKD affects roughly 37 million Americans, but 87% do not know they have it, PHTI noted, underscoring the gap between diagnosis rates and the scale of the condition. Traditional Medicare spends approximately $141 billion annually on people with CKD, while employers face an estimated $107 billion in direct costs tied to the disease, according to the institute's analysis.

Given the gap between investment and measurable outcomes, PHTI concluded that purchasers should rework their contracts and incentive programs to reward patient-level milestones more likely to slow disease progression, including earlier diagnosis and adoption of guideline-recommended medications, rather than paying for engagement or utilization metrics that don't correlate with clinical improvement.

The report adds to a growing body of scrutiny facing digital health vendors more broadly. As venture funding poured into virtual care and remote monitoring companies over the past several years, purchasers and providers have increasingly pushed back on vague value claims, demanding proof that digital health tools actually improve outcomes rather than simply digitizing existing workflows. PHTI's CKD evaluation follows a similar pattern to the institute's past assessments of other virtual chronic-disease management categories, which have also found thin evidence of cost or outcome benefits relative to their market valuations.

For physicians managing patients with CKD, the disconnect PHTI identifies is a familiar one: technology adoption has outpaced evidence generation. Nephrologists and primary care physicians have long pointed to early detection and consistent use of medications such as SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists as the interventions most likely to slow progression toward kidney failure. PHTI's findings suggest that virtual care platforms, as currently designed, are not reliably driving those specific clinical behaviors at scale, even though they may offer convenience or engagement benefits that fall short of measurable disease modification.

The institute's recommendation that purchasers redesign contracts around patient-level clinical milestones rather than utilization or engagement metrics reflects a broader shift in how health plans and employers are beginning to evaluate digital health vendors. Rather than accepting claims of cost avoidance or member satisfaction at face value, purchasers are increasingly asking vendors to demonstrate impact on hard clinical endpoints, a bar that PHTI's evaluation suggests most virtual CKD solutions have not yet cleared. With CKD's diagnosis rate remaining low and its cost burden continuing to climb, the pressure on both vendors and health systems to close that evidence gap is likely to intensify.